Biologics, like monoclonal antibodies and viral vectors, make up rapidly growing classes of drugs. They are also critical research tools and essential for the development of many new diagnostics.
While chromatography has been a mainstay for small molecules, large and bulky biologics require a new approach to downstream manufacturing. Isolere Bio was founded with the vision of simplifying and streamlining the purification of biologics to improve global access to these important therapeutics.
We are currently focused on developing this technology for the manufacturing of Fc fusion proteins and adeno-associated virus (AAV), as well as enveloped viruses, nucleic acids, and enzymes. We are working to develop a low-cost, high throughput, and scalable purification platform and we are actively seeking validation and scale-up partners who share our vision for the next generation of bioprocessing.
Our product is made entirely recombinantly in E. coli and has no synthetic scaffold. This eliminates the cost of the solid support and chemical conjugation steps.
Our process scales linearly, providing a seamless transition from the bench to the clinic and into commercialization.
EASE OF USE
Our technology requires a simple tangential flow filtration (TFF) setup rather than complex chromatography equipment. It is compatible with validated, off-the-shelf filters with large pore sizes that enable high volumetric throughput.
From high throughput 96-well plates, to all-in-one kits, to bulk reagent, our technology can be tailored to suit your needs. A residual ELISA will be commercially available prior to product launch and the reagent can be provided as either research- or GMP-grade.
Complete concentration and purification with TFF in 8 hours or less. High flux will eliminate the capture step bottleneck and permeate control enables seamless development of a continuous downstream processes.
Our reagent binds and elutes the target in solution, eliminating the mass transfer constraints of traditional packed bed chromatography
Innovative, chromatography-free solutions for the efficient and scalable purification of biologics, including viral vectors, antibodies/Fc fusions, and nucleic acids.
Isolere welcomes Reetu Singh, Linus Hyun, and Shaleen Shrestha to the team!
May 5, 2021
Isolere announces the closing of a $7M Series Seed financing round and is honored to join the Northpond Ventures portfolio. Read more here.
May 4, 2021
Isolere receives a Fast-Track award from the NIH to support its AAV manufacturing technology.
THE ISOTAG TECHNOLOGY
This process is highly platform-able! Contact us to discuss custom reagent development to your therapeutic of interest. By replacing the antibody-binding domain with a different capture domain at the gene level, this versatile technology can be applied to other biotherapeutics.
FOUNDER & CHAIRMAN OF THE BOARD
Ashutosh Chilkoti, PhD
FOUNDER & CHIEF SCIENTIFIC ADVISOR
Kelli Luginbuhl, PhD
FOUNDER & CHIEF EXECUTIVE OFFICER
Adam Wieschhaus, PhD, CFA
BOARD OF DIRECTORS
Michael Dzuricky, PhD
CHIEF SCIENTIFIC OFFICER
Rich McGivney, CPA
CHIEF FINANCIAL OFFICER
Yi Wang, PhD, MBA
VP Business Development
Isolere is hiring!
We are looking to fill several key positions:
Lead Scientist of mRNA R&D Program - lead the application of our technology to improve mRNA manufacturability and modification efficiency (posting)
Lead Engineer of Downstream Processing - take on a critical and challenging role in helping us to develop robust, scalable, and platform process solutions for diverse biologics applications (posting)